Bortolotti M
Department of Medicine and Gastroenterology, University of Bologna, Italy.
Digestion. 1999 Jan-Feb;60(1):11-6. doi: 10.1159/000007583.
The rationale for medical therapy of initial achalasia and the results obtained over the last 20 years in our laboratory are presented.
Achalasic patients were selected as candidates for medical therapy on the basis of the presence of a slight esophageal dilation (<5 cm) on X-rays and a good manometric response to nifedipine administration. These patients were asked to take 10-20 mg of nifedipine sublingually 30-45 min before each meal for 2 weeks. Chronic medical therapy was continued only in those with an 'excellent' or 'good' clinical response to nifedipine and a lack of severe side effects. X-ray controls were planned every 6 months and manometric examination after the first 6 months.
Of the 56 patients selected in the above-mentioned manner, 17 had an insufficient clinical response or severe side effects during the initial trial and did not continue medical therapy. Of the 39 patients who started chronic medical treatment, 13 are still on therapy and 26 stopped after an average of 2.8 years: 17 because they underwent dilation or myotomy; 4 for unknown reasons, and 5 apparently recovered. Esophageal manometry was carried out in 4 of the latter patients and revealed that the achalasic motor pattern had been replaced by a near-normal pattern.
We believe that medical treatment of achalasia should be carried out not only in those patients who cannot undergo invasive procedures or do not respond well to them, but also in patients with initial achalasia selected using the above-mentioned criteria, because regression of the disease could take place in some of them.
介绍了对初发性贲门失弛缓症进行药物治疗的基本原理以及过去20年在我们实验室所取得的结果。
根据X线显示食管轻度扩张(<5 cm)且对硝苯地平给药有良好的测压反应,选择贲门失弛缓症患者作为药物治疗的候选对象。这些患者被要求在每餐饭前30 - 45分钟舌下含服10 - 20毫克硝苯地平,持续2周。仅对硝苯地平有“优秀”或“良好”临床反应且无严重副作用的患者继续进行长期药物治疗。计划每6个月进行一次X线检查,并在最初6个月后进行测压检查。
以上述方式选择的56例患者中,17例在初始试验期间临床反应不佳或出现严重副作用,未继续药物治疗。在开始长期药物治疗的39例患者中,13例仍在接受治疗,26例在平均2.8年后停止治疗:17例是因为接受了扩张或肌切开术;4例原因不明,5例显然已康复。对后5例患者中的4例进行了食管测压,结果显示失弛缓性运动模式已被接近正常的模式所取代。
我们认为,贲门失弛缓症的药物治疗不仅应针对那些无法接受侵入性手术或对其反应不佳的患者,也应针对使用上述标准选择的初发性贲门失弛缓症患者,因为其中一些患者的病情可能会有所缓解。